statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil...

Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors

Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS)

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 9,000...

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Over the last three days, A.I.dvisor has detected that ATXS's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

Astria Therapeutics (ATXS, $13.49) Aroon Indicator entered an Uptrend on April 01, 2024.

This price move could indicate a change in the trend, and may be a sell signal for investors...

Astria Therapeutics (ATXS, $13.49) price exceeded its 50-day Moving Average on April 01, 2024

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling...

Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Update

Wedbush reiterated their outperform rating on shares of Astria Therapeutics (NASDAQ:ATXS  Free Report) in a research report released on Tuesday, Benzinga reports. The brokerage currently has...

Wedbush Reaffirms Outperform Rating for Astria Therapeutics (NASDAQ:ATXS)

Astria Therapeutics (ATXS, $13.6) Aroon Indicator entered an Uptrend on March 27, 2024.

Astria Therapeutics (ATXS, $13.53) Aroon Indicator entered an Uptrend on March 26, 2024.

This indicator may be signaling that ATXS's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Astria Therapeutics (ATXS, $13.53) entered Downtrend as Momentum indicator drops below 0 level on Mar 26, 2024

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

Volume	2.72M
52-Wk High	$16.90
52-Wk Low	$4.26

ATXS Astria Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals